Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.

  • Heme · ALLRecruitingPhase 3NCT07476729

    International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

    Charite University, Berlin, Germany · 21 locations · Updated 2026-10-26

  • Heme · ALL, LymphomaNot yet recruitingPhase 3NCT07774377

    Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma

    First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2026-08-19

  • Heme · ALLRecruitingPhase 3NCT04307576

    A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

    Mats Heyman · 137 locations · Updated 2026-08-12

  • Heme · ALLRecruitingPhase 2 / Phase 3NCT06764238

    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

    Institute of Hematology & Blood Diseases Hospital, China · 27 locations · Updated 2026-07-23

  • Heme · ALLRecruitingPhase 3NCT06051409

    A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

    Ascentage Pharma Group Inc. · 90 locations · Updated 2026-04-30

  • Heme · ALL, LymphomaRecruitingPhase 2 / Phase 3NCT07502118

    NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

    Health Institutes of Turkey · 4 locations · Updated 2026-03-30

  • Heme · ALLRecruitingPhase 3NCT07441291

    CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

    Peking University People's Hospital · 1 locations · Updated 2026-02-27

  • Heme · ALLRecruitingPhase 3NCT07152041

    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

    Institute of Hematology & Blood Diseases Hospital, China · 24 locations · Updated 2025-09-03

  • Heme · ALLRecruitingPhase 2 / Phase 3NCT06882057

    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

    Institute of Hematology & Blood Diseases Hospital, China · 27 locations · Updated 2025-08-26

  • Heme · ALL, LymphomaRecruitingPhase 2 / Phase 3NCT06855810

    Newly-diagnosed Pediatric T-cell ALL Protocol

    Institute of Hematology & Blood Diseases Hospital, China · 27 locations · Updated 2025-08-26

  • Heme · ALLRecruitingPhase 2 / Phase 3NCT06607419

    Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

    Shanghai Jiao Tong University School of Medicine · 4 locations · Updated 2024-09-23

  • Heme · ALLRecruitingPhase 3NCT05029531

    Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

    Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 locations · Updated 2024-06-28

  • Heme · ALLRecruitingPhase 2NCT06317662

    Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    National Cancer Institute (NCI) · 117 locations · Updated 2026-11-18

  • Heme · ALLRecruitingPhase 2NCT07301138

    BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

    Ruijin Hospital · 1 locations · Updated 2026-11-17

  • Heme · ALLRecruitingPhase 2NCT05289687

    Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

    Eastern Cooperative Oncology Group · 1 locations · Updated 2026-11-16

  • Heme · ALLRecruitingPhase 2NCT04546399

    A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    National Cancer Institute (NCI) · 229 locations · Updated 2026-11-12

  • Heme · ALLRecruitingPhase 2NCT06718244

    Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

    Ruijin Hospital · 1 locations · Updated 2026-11-12

  • Heme · ALLRecruitingPhase 1 / Phase 2NCT05848687

    TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

    Tanja Andrea Gruber · 24 locations · Updated 2026-11-12

  • Heme · ALLNot yet recruitingPhase 1 / Phase 2NCT07313852

    A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

    Memorial Sloan Kettering Cancer Center · 1 locations · Updated 2026-11-09

  • Heme · ALLNot yet recruitingPhase 2NCT07862946

    Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia

    PETHEMA Foundation · 10 locations · Updated 2026-11-04

  • Heme · ALLRecruitingPhase 2NCT05519579

    Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

    Northside Hospital, Inc. · 1 locations · Updated 2026-10-14

  • Heme · ALLNot yet recruitingPhase 2NCT07636564

    Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment

    SWOG Cancer Research Network · Locations not reported · Updated 2026-10-13

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06514794

    A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

    Allotera Therapeutics · 18 locations · Updated 2026-09-28

  • Heme · ALLRecruitingPhase 2NCT06144606

    Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    H. Lee Moffitt Cancer Center and Research Institute · 1 locations · Updated 2026-09-25

  • Heme · ALL, LymphomaRecruitingPhase 1 / Phase 2NCT04544592

    UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

    University of Colorado, Denver · 1 locations · Updated 2026-09-14

  • Heme · ALLRecruitingPhase 2NCT06648889

    Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

    Goethe University · 15 locations · Updated 2026-08-28

  • Heme · ALLRecruitingPhase 2NCT07400029

    A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

    Memorial Sloan Kettering Cancer Center · 9 locations · Updated 2026-08-20

  • Heme · ALL, LymphomaRecruitingPhase 1 / Phase 2NCT07070219

    A Study of CTD402 in T-ALL/LBL Patients

    Imviva Bio · 9 locations · Updated 2026-08-19

  • Heme · ALLRecruitingPhase 2NCT05082519

    Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

    Etan Orgel · 16 locations · Updated 2026-08-19

  • Heme · ALLNot yet recruitingPhase 2NCT07301424

    Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

    University of Alberta · 1 locations · Updated 2026-08-12

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06390319

    Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

    St. Jude Children's Research Hospital · 4 locations · Updated 2026-08-10

  • Heme · ALLRecruitingPhase 2NCT05827549

    Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

    Ho Joon Im · 10 locations · Updated 2026-07-29

  • Heme · ALLRecruitingPhase 2NCT06099366

    Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

    Hee Young Ju · 13 locations · Updated 2026-07-29

  • Heme · ALLRecruitingPhase 2NCT06257394

    Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

    Hyoung Jin Kang · 10 locations · Updated 2026-07-29

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06533748

    Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

    St. Jude Children's Research Hospital · 3 locations · Updated 2026-07-16

  • Heme · Myeloma, ALL, CLL, AML, LymphomaRecruitingPhase 2NCT03314974

    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

    Masonic Cancer Center, University of Minnesota · 1 locations · Updated 2026-06-25

  • Heme · ALLNot yet recruitingPhase 2NCT07643103

    Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-06-11

  • Heme · ALL, LymphomaRecruitingPhase 1 / Phase 2NCT05480449

    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

    Stephan Grupp MD PhD · 1 locations · Updated 2026-05-26

  • Heme · ALL, LymphomaRecruitingPhase 2NCT07566377

    Cord Blood Transplantation in Children and Young Adults With Blood Cancer

    Memorial Sloan Kettering Cancer Center · 1 locations · Updated 2026-05-14

  • Heme · ALLRecruitingPhase 1 / Phase 2NCT06481735

    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

    Chinese PLA General Hospital · 6 locations · Updated 2026-05-08

Showing 1–40 of 101. Older studies

More hematologic trials (86) that list MRD only as a secondary endpoint
  • Heme · ALLRecruitingPhase 2 / Phase 3NCT07570173

    A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

    Merck Sharp & Dohme LLC · 30 locations · Updated 2026-11-10

  • Heme · ALLRecruitingPhase 3NCT05327894

    Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

    Princess Maxima Center for Pediatric Oncology · 124 locations · Updated 2026-10-19

  • Heme · ALLNot yet recruitingPhase 3NCT07223190

    A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia

    Amgen · Locations not reported · Updated 2026-09-15

  • Heme · ALLNot yet recruitingPhase 3NCT07723911

    A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-07-23

  • Heme · ALLRecruitingPhase 2 / Phase 3NCT06860269

    A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia

    Assistance Publique - Hôpitaux de Paris · 1 locations · Updated 2026-02-10

  • Heme · ALLRecruitingPhase 3NCT03643276

    Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

    Martin Schrappe · 115 locations · Updated 2025-04-06

  • Heme · ALLRecruitingPhase 2NCT03739814

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    National Cancer Institute (NCI) · 285 locations · Updated 2026-11-18

  • Heme · ALLNot yet recruitingPhase 2NCT07940621

    Inotuzumab Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALL

    Ruijin Hospital · Locations not reported · Updated 2026-11-17

  • Heme · ALL, AMLNot yet recruitingPhase 2NCT07937124

    An All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)

    First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2026-11-13

  • Heme · ALLRecruitingPhase 1 / Phase 2NCT07109219

    Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

    AstraZeneca · 27 locations · Updated 2026-11-13

  • Heme · ALLRecruitingPhase 1 / Phase 2NCT07387926

    Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

    Novartis Pharmaceuticals · 9 locations · Updated 2026-11-12

  • Heme · ALL, AMLNot yet recruitingPhase 1 / Phase 2NCT07926607

    Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

    Second Affiliated Hospital of Nanchang University · 1 locations · Updated 2026-11-09

  • Heme · ALLRecruitingPhase 1 / Phase 2NCT05579132

    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

    MSD R&D (China) Co., Ltd. · 11 locations · Updated 2026-10-30

  • Heme · ALLRecruitingPhase 2NCT06124157

    A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    National Cancer Institute (NCI) · 161 locations · Updated 2026-10-27

  • Heme · ALLNot yet recruitingPhase 1 / Phase 2NCT07890025

    CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study

    Hospital Universitario Dr. Jose E. Gonzalez · 1 locations · Updated 2026-10-22

  • Heme · ALL, AMLRecruitingPhase 2NCT03970096

    Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    Fred Hutchinson Cancer Center · 3 locations · Updated 2026-10-20

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06918431

    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    City of Hope Medical Center · 8 locations · Updated 2026-10-13

  • Heme · ALLRecruitingPhase 1 / Phase 2NCT06137118

    AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

    AstraZeneca · 83 locations · Updated 2026-10-13

  • Heme · ALLNot yet recruitingPhase 2NCT07840976

    Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-09-25

  • Heme · ALLRecruitingPhase 2NCT05334823

    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

    Chongqing Precision Biotech Co., Ltd · 16 locations · Updated 2026-09-15

  • Heme · ALL, CLL, LymphomaNot yet recruitingPhase 2NCT07812246

    Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial

    City of Hope Medical Center · 3 locations · Updated 2026-09-10

  • Heme · ALLRecruitingPhase 2NCT07227584

    ALL Backbone in AYAs

    Dana-Farber Cancer Institute · 1 locations · Updated 2026-08-17

  • Heme · ALL, LymphomaRecruitingPhase 2NCT02877303

    Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-05-20

  • Heme · ALLRecruitingPhase 2NCT07564453

    Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-05-04

  • Heme · Myeloma, ALL, CLL, AML, LymphomaRecruitingPhase 1 / Phase 2NCT07523555

    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

    Beijing Biotech · 1 locations · Updated 2026-04-13

  • Heme · ALL, LymphomaRecruitingPhase 1 / Phase 2NCT05674175

    Co-administration of CART22-65s and huCART19 for B-ALL

    Stephan Grupp MD PhD · 1 locations · Updated 2026-03-27

  • Heme · ALLRecruitingPhase 2NCT03590171

    International Study for Treatment of High Risk Childhood Relapsed ALL 2010

    Charite University, Berlin, Germany · 15 locations · Updated 2026-03-17

  • Heme · ALL, AMLRecruitingPhase 1 / Phase 2NCT07471789

    Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

    Gyala Therapeutics · 2 locations · Updated 2026-03-13

  • Heme · ALLRecruitingPhase 2NCT04276870

    Orphan Indications for CD19 Redirected Autologous T Cells

    Stephan Grupp MD PhD · 1 locations · Updated 2026-03-06

  • Heme · ALL, AML, LymphomaRecruitingPhase 1 / Phase 2NCT07153068

    SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-12-15

  • Heme · ALL, AMLRecruitingPhase 2NCT07256210

    Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

    Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 locations · Updated 2025-12-01

  • Heme · ALLRecruitingPhase 2NCT07039877

    Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

    Hospital Universitario Dr. Jose E. Gonzalez · 1 locations · Updated 2025-10-02

  • Heme · ALLRecruitingPhase 1 / Phase 2NCT05667506

    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

    Juventas Cell Therapy Ltd. · 9 locations · Updated 2025-08-12

  • Heme · ALLRecruitingPhase 2NCT04684147

    Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

    Juventas Cell Therapy Ltd. · 11 locations · Updated 2025-08-08

  • Heme · ALLNot yet recruitingPhase 2NCT06777264

    Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

    First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2025-01-15

  • Heme · ALLRecruitingPhase 2NCT06179524

    CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

    Beijing Yongtai Ruike Biotechnology Company Ltd · 1 locations · Updated 2025-01-13

  • Heme · ALL, CLL, LymphomaRecruitingPhase 2NCT05281809

    Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

    John Lister · 1 locations · Updated 2025-01-13

  • Heme · ALLRecruitingPhase 2NCT06754267

    Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

    First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-12-31

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06742463

    VHAG in Treating R/R T-ALL/LBL

    First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-12-19

  • Heme · ALLRecruitingPhase 1 / Phase 2NCT06635330

    Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

    Kara Yakhteh Tajhiz Azma Company · 1 locations · Updated 2024-10-10

  • Heme · ALLRecruitingPhase 2NCT06554626

    Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

    First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-08-15

  • Heme · ALLRecruitingNot reportedObservationalNCT07938333

    Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology Patients

    Children's Hospital of Orange County · 1 locations · Updated 2026-11-16

  • Heme · ALL, LymphomaRecruitingPhase 1NCT06173518

    A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    Autolus Limited · 15 locations · Updated 2026-11-13

  • Heme · ALLRecruitingPhase 1NCT07927816

    CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

    Liping Dou · 1 locations · Updated 2026-11-10

  • Heme · ALLNot yet recruitingNot applicableNCT07919470

    Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT

    Peking University People's Hospital · 1 locations · Updated 2026-11-05

  • Heme · ALLRecruitingPhase 1NCT07040982

    Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    City of Hope Medical Center · 1 locations · Updated 2026-11-03

  • Heme · ALLNot yet recruitingPhase 1NCT07914166

    Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    City of Hope Medical Center · 1 locations · Updated 2026-11-03

  • Heme · ALLRecruitingPhase 1NCT07614022

    A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)

    Wake Forest University Health Sciences · 2 locations · Updated 2026-10-29

  • Heme · ALL, AMLRecruitingPhase 1NCT06575296

    Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

    City of Hope Medical Center · 1 locations · Updated 2026-10-19

  • Heme · ALLRecruitingPhase 1NCT07133997

    Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

    City of Hope Medical Center · 1 locations · Updated 2026-10-16

  • Heme · ALL, LymphomaRecruitingPhase 1NCT06208735

    CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

    British Columbia Cancer Agency · 7 locations · Updated 2026-10-14

  • Heme · ALLRecruitingPhase 1NCT07838714

    Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia

    Ruijin Hospital · 1 locations · Updated 2026-09-25

  • Heme · ALLNot yet recruitingEarly Phase 1NCT07830238

    SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

    Shanghai Simnova Biotechnology Co.,Ltd. · 1 locations · Updated 2026-09-21

  • Heme · ALL, LymphomaRecruitingPhase 1NCT07350863

    U69-CART-Cells For R/R T-ALL

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-09-02

  • Heme · ALL, LymphomaRecruitingPhase 1NCT07586618

    First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

    Allterum Therapeutics, Inc · 7 locations · Updated 2026-09-01

  • Heme · ALLRecruitingPhase 1NCT05495035

    Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

    Institute of Hematology & Blood Diseases Hospital, China · 4 locations · Updated 2026-08-26

  • Heme · ALLRecruitingNot applicableNCT07371403

    MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

    King Hussein Cancer Center · 1 locations · Updated 2026-08-05

  • Heme · ALL, LymphomaRecruitingNot reportedObservationalNCT06785818

    Long-term Follow up Local Registry Study of Kymriah in South Korea

    Novartis Pharmaceuticals · 18 locations · Updated 2026-07-30

  • Heme · ALLRecruitingNot applicableNCT07493161

    Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-07-23

  • Heme · ALLRecruitingPhase 1NCT03571321

    Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

    University of Chicago · 2 locations · Updated 2026-06-29

  • Heme · ALLNot yet recruitingNot reportedObservationalNCT07637929

    Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

    Chongqing Precision Biotech Co., Ltd · Locations not reported · Updated 2026-06-10

  • Heme · ALL, LymphomaNot yet recruitingPhase 1NCT07539610

    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-04-20

  • Heme · ALLRecruitingEarly Phase 1NCT07470073

    A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2026-03-13

  • Heme · ALLRecruitingEarly Phase 1NCT06890494

    Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia

    Beijing GoBroad Hospital · 1 locations · Updated 2026-03-10

  • Heme · ALLRecruitingPhase 1NCT05581030

    CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

    H. Lee Moffitt Cancer Center and Research Institute · 1 locations · Updated 2026-03-06

  • Heme · ALLRecruitingPhase 1NCT07078929

    Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

    Chulalongkorn University · 3 locations · Updated 2026-03-02

  • Heme · ALLRecruitingNot applicableNCT06481241

    Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-03-02

  • Heme · ALLRecruitingNot applicableNCT06481228

    Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-03-02

  • Heme · ALLNot yet recruitingNot applicableNCT07443592

    Treatment for Ph-negative ALL for Adults up to 65 Years

    PETHEMA Foundation · 95 locations · Updated 2026-03-02

  • Heme · ALLRecruitingNot applicableNCT06389305

    CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

    Beijing GoBroad Hospital · 1 locations · Updated 2026-02-25

  • Heme · ALLRecruitingEarly Phase 1NCT07429461

    Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

    Zhejiang University · 1 locations · Updated 2026-02-24

  • Heme · ALLNot yet recruitingNot applicableNCT06991920

    Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-02-11

  • Heme · ALLRecruitingPhase 1NCT07361029

    CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia

    King Faisal Specialist Hospital & Research Center · 1 locations · Updated 2026-01-22

  • Heme · ALLNot yet recruitingEarly Phase 1NCT07277504

    Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

    The General Hospital of Western Theater Command · 1 locations · Updated 2025-12-11

  • Heme · ALLRecruitingNot reportedObservationalNCT07258043

    Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia

    Hospital General de Mexico · 1 locations · Updated 2025-12-02

  • Heme · ALLNot yet recruitingEarly Phase 1NCT07256353

    Allogeneic UCB-derived CAR-T for B-ALL

    The General Hospital of Western Theater Command · 1 locations · Updated 2025-12-01

  • Heme · ALLRecruitingPhase 1NCT06559189

    CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

    University of Colorado, Denver · 1 locations · Updated 2025-11-28

  • Heme · ALL, LymphomaNot yet recruitingPhase 1NCT07234045

    A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-11-18

  • Heme · ALLRecruitingPhase 1NCT03595917

    ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

    Marlise Luskin, MD · 4 locations · Updated 2025-11-04

  • Heme · ALLRecruitingNot applicableNCT06785324

    Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

    University of Chicago · 1 locations · Updated 2025-06-19

  • Heme · ALLNot yet recruitingEarly Phase 1NCT06849401

    The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia

    Shanghai Jiao Tong University School of Medicine · Locations not reported · Updated 2025-05-15

  • Heme · ALL, LymphomaRecruitingNot applicableNCT06866873

    CD-19 CAR-T Cell for Pediatric ALL or Lymphoma

    Hong Kong Children's Hospital · 1 locations · Updated 2025-03-10

  • Heme · ALL, AMLRecruitingNot reportedObservationalNCT05326919

    The Patient Cohort of the National Center for Precision Medicine in Leukemia

    Assistance Publique - Hôpitaux de Paris · 3 locations · Updated 2024-05-29

  • Heme · ALLRecruitingNot applicableNCT04179929

    Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

    PETHEMA Foundation · 108 locations · Updated 2022-02-18

  • Heme · ALL, LymphomaRecruitingEarly Phase 1NCT04227015

    A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

    He Huang · 1 locations · Updated 2020-12-28

  • Heme · ALLNot yet recruitingPhase 1NCT04595162

    A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

    Peking University Third Hospital · Locations not reported · Updated 2020-10-20

Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.